Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information   
Inhaled Ventavis® (iloprost) Inhalation Solution Breathe In the Power of Prostacyclin In Pulmonary Arterial Hypertension (PAH) NYHA Class III or IV
About the I-neb AAD
System
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

About the I-neb AAD System

The I-neb AAD System is a battery-powered pulmonary drug delivery system that makes it possible for patients to take their Ventavis® (iloprost) Inhalation Solution treatments almost anywhere. With up to 40 treatments from a single charge, the I-neb AAD System frees patients from the need to be near an electrical outlet. Because the I-neb AAD System is portable and virtually silent, patients may find it easier to comply with their prescribed dosing regimen. Finally, with Adaptive Aerosol Delivery (AAD) technology, you can be sure that your patients are receiving an accurate dose.

Use the I-neb AAD System to dispense Ventavis. Standard air-jet nebulizers/compressors or ultrasonic nebulizer systems, such as those used to deliver inhalation solutions for asthma, are continuous flow systems that constantly generate aerosol. Patients typically have a 40:60 inhalation:exhalation ratio; therefore, about 60% of the drug is wasted to the environment with such devices during exhalation.1 Additionally, a variable amount of drug is inhaled by each patient because individual breathing patterns differ (e.g., short, shallow breaths to long, deep breaths).

Specifically designed for use with Ventavis

Variable dosing is acceptable for drugs with a broad therapeutic window (e.g., albuterol and ipratropium bromide); however, Ventavis is a potent prostacyclin analogue with a narrow therapeutic index. Precise, reproducible dosing of Ventavis to every patient is required for the safety and efficacy of the drug.

Delivers precise doses to every patient

The system uses AAD technology to precisely and reproducibly deliver Ventavis to every patient, at either dose (2.5 mcg or 5.0 mcg), using a single ampule of medication. The dose each patient receives is controlled by the medication chamber. The I-neb AAD System continuously monitors and analyzes a patient's breathing pattern and delivers pulses of aerosol into the start of each inhalation until the set dose is delivered.

One ampule per treatment

Only one drug treatment (either 2.5 mcg or 5.0 mcg) can be delivered from the contents of a single ampule. Reuse of any drug solution that remains after completing a drug treatment, even if the reservoir is "topped off" with fresh medication, will not give accurate dosing. Do not reuse ampules.

Read more about the I-neb ADD System:

  • Components
  • How it works
  • Cleaning the I-neb AAD System
  • Breathing Technique
  • I-neb AAD Learning Center

    • I-neb AAD System User Guide
    The I-neb AAD System is a registered trademark of Philips Respironics.

    1. Denyer J, Nikander K, Smith NJ. Adaptive Aerosol Delivery (AAD) technology. Expert Opin Drug Deliv. 2004;1:165-176.



    * In the AIR pivotal trial, Ventavis delivered significant patient improvement in a composite endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

    IMPORTANT SAFETY INFORMATION:
    In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

    Please see full Prescribing Information

    For more information about
    Ventavis, please call
    1-866-ACTELION (1-866-228-3546).

    Policies & Disclaimers  |  Contact Us  |  Site Map  |  Important Safety Information

    THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
    SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
    ©2010 Actelion Pharmaceuticals US, Inc. All rights reserved.

    		ACTELION